Is this good news actually bad news for shareholders? Per the results of a phase 3 clinical trial reported Feb. 5, Vertex's latest candidate for treating cystic fibrosis (CF), a rare and serious ...
Wondering if Vertex Pharmaceuticals at around US$424 per share is still a solid opportunity or if the easy gains are behind ...
Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The ...
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...
I expect that some things that are true for Vertex today will still be applicable five years from now. For one thing, the company will remain the dominant player in the CF market. Sure, a handful of ...
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), today announced a global, multi-target license and option agreement ...
Google updated the documentation for the Google-Extended user agent, which publishers can use to control whether Google Gemini and Vertex use their data for training purposes or for grounding AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results